Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Mallinckrodt
Moodys
Dow
AstraZeneca

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ROZEREM

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Rozerem

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00316992 Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease Completed Takeda Phase 4 2006-04-01 The purpose of this study is to determine if ramelteon has respiratory depressant effects in subjects with moderate to severe chronic obstructive pulmonary disease.
NCT00325728 Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease Completed Takeda Phase 2 2006-03-01 The purpose of this study is to determine the efficacy of ramelteon, once daily (QD), in subjects with mild to moderate Alzheimer's Disease and sleep disturbance
NCT00391755 A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches Terminated Takeda Pharmaceuticals North America, Inc. Phase 4 2006-10-01 To study the effect of Rozerem, a high affinity MT1 and MT2, low affinity 5-HT2B receptor agonist used for insomnia, as a migraine prophylactic agent.
NCT00391755 A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches Terminated Charlottesville Neuroscience Phase 4 2006-10-01 To study the effect of Rozerem, a high affinity MT1 and MT2, low affinity 5-HT2B receptor agonist used for insomnia, as a migraine prophylactic agent.
NCT00414102 Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia. Completed Takeda Phase 4 2006-10-01 The purpose of this study is to determine the subjective treatment effects of ramelteon, once daily (QD), on sleep using a post sleep questionnaire-interactive voice response system in adults with chronic insomnia.
NCT00462254 Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease Terminated Southern California Institute for Research and Education Phase 4 2007-06-01 Patients with Parkinson's disease represent a significant proportion of VA elderly patients. Sleep disturbances and caregiver burnout association with this condition represent a significant problem. In this study, the investigators propose to perform an evaluation of a fixed doe of ramelteon on sleep in VA outpatients diagnosed with Parkinson's disease. The hypothesis to be examined is that ramelteon will improve the quality of sleep in patients with Parkinson's disease while indirectly improving the quality of life for the patients and caregivers. The investigators further hypothesize that these changes will occur through restructuring and normalization of the sleep architecture.
NCT00568789 Safety of Ramelteon in Elderly Subjects Completed Takeda Phase 4 2006-06-01 The purpose of this study is to investigate the effects of ramelteon in elderly subjects on balance, mobility and memory impairment after awakening in the middle of the night following bedtime dosing.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rozerem

Condition Name

Condition Name for Rozerem
Intervention Trials
Insomnia 8
Chronic Insomnia 5
Bipolar Disorder 2
Sleep Initiation and Maintenance Disorders 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Rozerem
Intervention Trials
Sleep Initiation and Maintenance Disorders 14
Parasomnias 2
Dyssomnias 2
Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Rozerem

Trials by Country

Trials by Country for Rozerem
Location Trials
United States 89
Japan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Rozerem
Location Trials
California 7
Florida 6
New York 5
Ohio 5
Kentucky 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Rozerem

Clinical Trial Phase

Clinical Trial Phase for Rozerem
Clinical Trial Phase Trials
Phase 4 11
Phase 3 5
Phase 2 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Rozerem
Clinical Trial Phase Trials
Completed 14
Terminated 4
Unknown status 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Rozerem

Sponsor Name

Sponsor Name for Rozerem
Sponsor Trials
Takeda 15
Southern California Institute for Research and Education 1
Southern Arizona VA Health Care System 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Rozerem
Sponsor Trials
Industry 16
Other 11
U.S. Fed 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
McKinsey
Baxter
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.